Backward Walking Rehabilitation to Prevent Falls in High-risk Adults Aged 75 Years and Older

NCT07650097 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-08-31

No results posted yet for this study

Summary

Falls are a major health problem for people aged 75 or older. Backward walking may strengthen the muscles of the legs, improve posture and balance, and make walking more stable, which could help prevent new falls and improve everyday movement.

This is an open-label, multicenter, randomized controlled trial that will examine whether backward walking, integrated to usual rehabilitation in a geriatric day hospital program, can help reduce the number of new falls in older adult at high risk of falling.

About 300 people aged 75 years or older, living at home and at high risk of falling, will be included in this trial in 11 geriatric day hospitals in France. After receiving appropriate information, those who agree to participate will sign a written consent form and will then be randomly assigned to one of two groups. Both groups will receive standard rehabilitation care in the geriatric day hospital, with two rehabilitation sessions per week for 12 weeks. In the control group, patients will only receive usual care to prevent falls previously described above. In the intervention group, part of the usual care will be replaced, for 5 weeks, by supervised backward walking exercises, with the goal of doing two effective 10 minute backward walking sessions per week, without increasing the total time spent in rehabilitation.

The trial will be conducted under the intention-to-treat principle. Participants will have a clinical visit at day 0, at week 5 and at 6 months, during which clinical information and data related to their usual care and to the study will be collected. All participants will be followed for a total of 12 months, with monthly phone calls from a study team member to record any new falls, hospitalizations, health problems, or other important events. For 10 patients in the intervention group, an individual interview will also be carried out at the 5 week visit to better understand their experience of backward walking. 2 focus groups will be held with 2 randomly selected centers to identify barriers and facilitators to the implementation of backward walking sessions.

This study aims to determine whether adding backward walking to standard rehabilitation is a safe, acceptable and effective way to prevent falls in older adults at high risk of falling.

Conditions

  • High Risk of Falling

Interventions

OTHER

Walking backwards

Standard care combined with rehabilitation sessions involving walking backwards. Ten rehabilitation sessions involving walking backwards are scheduled, at a rate of two sessions per week for five weeks, on a secure treadmill designed for walking backwards. Walking backwards will not add to the rehabilitation time; it will replace standard care to allow for two 10-minute sessions of actual walking backwards per week. Walking backwards are integrated to the 12 weeks standard program.

OTHER

Usual walking

The standard program runs for 12 weeks, with sessions twice a week, comprising two 45-minute activities per day. At least one session per week must include balance training, muscle strengthening and multi-modal exercises. The treadmill may be used for these activities, but only for walking forwards.

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Bruno OQUENDO, Dr · Hôpital Charles-Foix - Assistance Publique Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-15
Primary Completion
2029-05-15
Completion
2029-05-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07650097 on ClinicalTrials.gov